Page 78 - TequioVol1No2

76 Cáncer hepático /Ramírez et al./69-77

Bibliografía Globocan. (2012). (IARC) Section of Cancer
Alfaro, J. A., Sinha, A., Kislinger, T. y Boutros, P. C. Surveillance.
(2014). Onco-proteogenomics: cancer proteomics
joins forces with genomics. Nat Methods, 11, Gomaa, A. I., Khan, S. A., Toledano, M. B., Waked, I. y
1107e13. Taylor-Robinson, S. D. (2008). Hepatocellular carcinoma:
epidemiology, risk factors and pathogenesis. World J
Assy, N., Nasser, G., Djibre, A., Beniashvili, Z., Elias, Gastroenterol, 14(27), 4300-4308.
S. y Zidan, J. (2009).Características de las lesiones
hepáticas sólidas comunes y recomendaciones para Gopal, D. V. y Rosen, H. R. (2000). Abnormal findings on
el diagnóstico. World J Gastroenterol., 15(26), 3217- liver function tests. Postgrad Med., 107(2), 100-114.
3227.
Hanahan, D. y Weinberg, R. A. (2000). The hallmarks
Barquera, S., Campos-Nonato, I., Hernández-Barrera, of cancer. Cell., 100(1), 57-70.
L., Pedroza, A. y Rivera-Dommarco, J. A. (2012).
Prevalencia de obesidad en adultos mexicanos. Kitisin, K1, Pishvaian, M. J., Johnson, L. B. y Mishra,
ENSANUT, 55(suppl), S151-S160. L. (2007). Liver stem cells and molecular signaling
pathways in hepatocellular carcinoma. Gastrointest
Chen, Y. Chen, J., Liu, Y., Li, S. y Huang, P. (2015). Cancer Res., 1(4 Suppl 2), S13-21.
Plasma miR-15b-5p, miR-338-5p and miR-764 as
Biomarkers for Hepatocellular Carcinoma. Med Sci Kumar, V., Abbas, A. y Aster, J. (2016). Patología
Monit., 21, 1864-1871. estructural y funcional. 9 ed. Barcelona: Elsevier.

Cornett, P. A. y Dea, T. O. (2015). Diagnóstico clínico Li, L. M., Hu, Z. B., Zhou, Z. X., Chen, X., Liu, F. Y.,
y tratamiento. 54 ed. Mcgraw-Hill/Interamericana Zhang, J. F., Shen, H. B., Zhang, C. Y. y Zen, K. (2010).
editores, S.A. de C.V. Serum microRNA profiles serve as novel biomarkers
for HBV infection and diagnosis of HBV-positive
Debs, T., Kassir, R., Amor, I. B., Martini, F., Iannelli, hepatocarcinoma. Cancer Res., 70, 9798-9807.
A. y Gugenheim, J. (2014). Solitary fibrous tumor
of the liver: report of two cases and review of the Li, S., Li, J., Fei, B. Y., Shao, D., Pan, Y., Mo, Z. H., Sun,
literature. Nt J Surg, 12(12), 1291-1294. B. Z, Zhang, D., Zheng, X., Zhang M., Zhang, X. W.
y Chen, L. (2015). MiR-27a promotes hepatocellular
Dufour, D. R., Lott, J. A., Nolte, F. S., Gretch, D. R., Koff, carcinoma cell proliferation through suppression of
R. S. y Seeff, L. B. (2000). Diagnosis and monitoring its target gene peroxisome proliferator-activated
of hepatic injury. I. Performance characteristics of receptor . Chin Med J., 128(7), 941-947.
laboratory tests. Lin Chem, 46(12), 2027-2049.
Liu, A. M., Yao, T. J., Wang, W., Wong, K. F., Lee, N.
Flores-Téllez, T. N. J., López, T. V., Vásquez-Garzón, V. P., Fan, S. T., Poon, R. T., Gao, C. y Luk, J. M. (2012).
R. y Villa-Treviño, S. (2015). Co-Expression of Ezrin- Circulating miR-15b and miR-130b in serum as
CLIC5-Podocalyxin is associated with migration and potential markers for detecting hepatocellular
invasiveness in hepatocellular carcinoma. PLoS ONE, carcinoma: a retrospective cohort study. BMJ Open,
10(7), e0131605. 2(2), e000825.

Tequio, vol. 1, no. 2, enero-abril, 2018